Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Sarah Sammons"'
Autor:
Alex Schick, Sara Hardy, Myla Strawderman, Dandan Zheng, Michael Cummings, Michael T. Milano, Allison Magnuson, Jacqueline Behr, Sarah Sammons, Kenneth Usuki, Nimish Mohile, Ruth O’Regan, Carey K. Anders, David Hicks, Ajay Dhakal
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-9 (2024)
Abstract The objective of the study is to assess impact of systemic disease (SD) status on overall survival and brain metastasis (BM) control, adopting a novel landmark approach to categorize SD among breast cancer (BC) patients. This single institut
Externí odkaz:
https://doaj.org/article/08d73478060c4e5ba9c384f5637ac6ea
Autor:
Laura Alder, Dario Trapani, Claire Bradbury, Amanda E. D. Van Swearingen, Sara M. Tolaney, Mustafa Khasraw, Carey K. Anders, Christopher D. Lascola, Liangge Hsu, Nancy U. Lin, Sarah Sammons
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-5 (2023)
Abstract Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%)
Externí odkaz:
https://doaj.org/article/c1b60de0ae2644269e08499f1c0de607
Autor:
Sarah Sammons, Andrew Elliott, Romualdo Barroso-Sousa, Saranya Chumsri, Antoinette R. Tan, George W. Sledge, Sara M. Tolaney, Evanthia T. Roussos Torres
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundData supporting high tumor mutational burden (TMB-H) as a lone biomarker for an immune-responsive tumor microenvironment (TME) in metastatic breast cancer (MBC) are weak, yet tumor agnostic approval in TMB-H advanced tumors provides immune
Externí odkaz:
https://doaj.org/article/8b0d35ab3ce5400f8a02d8f094918d24
Autor:
Ipshita Prakash, N. Ben Neely, Samantha M. Thomas, Sarah Sammons, Rachel C. Blitzblau, Gayle A. DiLalla, Terry Hyslop, Carolyn S. Menendez, Jennifer K. Plichta, Laura H. Rosenberger, Oluwadamilola M. Fayanju, E. Shelley Hwang, Rachel A. Greenup
Publikováno v:
Cancer Medicine, Vol 11, Iss 4, Pp 1099-1108 (2022)
Abstract Background Controversy exists regarding the optimal sequence of chemotherapy among women with operable node‐negative breast cancers with high‐risk tumor biology. We evaluated national patterns of neoadjuvant chemotherapy (NACT) use among
Externí odkaz:
https://doaj.org/article/17bacb17c23f4bb29164cca8bf68449c
Publikováno v:
Cancers, Vol 15, Iss 15, p 3997 (2023)
Tumor mutational burden (TMB) correlates with tumor neoantigen burden, T cell infiltration, and response to immune checkpoint inhibitors in many solid tumor types. Based on data from the phase II KEYNOTE-158 study, the anti-PD-1 antibody pembrolizuma
Externí odkaz:
https://doaj.org/article/40a6c968d50743ae8b02841eac165646
Autor:
Abhenil Mittal, Consolacion Molto Valiente, Faris Tamimi, Ilana Schlam, Sarah Sammons, Sara M. Tolaney, Paolo Tarantino
Publikováno v:
Cancers, Vol 15, Iss 7, p 2015 (2023)
The rise of cyclin-dependent kinase (CDK)4/6 inhibitors has rapidly reshaped treatment algorithms for hormone receptor (HR)-positive metastatic breast cancer, with endocrine treatment (ET) plus a CDK4/6-inhibitor currently representing the standard o
Externí odkaz:
https://doaj.org/article/1c5b50fd9bff45e9b71c0b003063f8ab
Autor:
Li Zhu, Jessica L. Narloch, Sayali Onkar, Marion Joy, Gloria Broadwater, Catherine Luedke, Allison Hall, Rim Kim, Katherine Pogue-Geile, Sarah Sammons, Naema Nayyar, Ugonma Chukwueke, Priscilla K. Brastianos, Carey K. Anders, Adam C. Soloff, Dario A. A. Vignali, George C. Tseng, Leisha A. Emens, Peter C. Lucas, Kimberly L. Blackwell, Steffi Oesterreich, Adrian V. Lee
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-10 (2019)
Abstract The interplay between the immune system and tumor progression is well recognized. However, current human breast cancer immunophenotyping studies are mostly focused on primary tumors with metastatic breast cancer lesions remaining largely und
Externí odkaz:
https://doaj.org/article/c2fc89921000427ea6b01395b0309364
Autor:
Laura Noteware, Gloria Broadwater, Nicole Dalal, Laura Alder, James E. Herndon II, Scott Floyd, William Giles, Amanda E. D. Van Swearingen, Carey K. Anders, Sarah Sammons
Publikováno v:
Breast Cancer Research and Treatment. 197:425-434
Current systemic therapy guidelines for patients with HER2 + breast cancer brain metastases (BCBrM) diverge based on the status of extracranial disease (ECD). An in-depth understanding of the impact of ECD on outcomes in HER2 + BCBrM has never been p
Autor:
Sheheryar Kabraji, Jing Ni, Sarah Sammons, Tianyu Li, Amanda E.D. Van Swearingen, Yanzhi Wang, Alyssa Pereslete, Liangge Hsu, Pamela J. DiPiro, Chris Lascola, Heather Moore, Melissa Hughes, Akshara S. Raghavendra, Maria Gule-Monroe, Rashmi K. Murthy, Eric P. Winer, Carey K. Anders, Jean J. Zhao, Nancy U. Lin
Publikováno v:
Clin Cancer Res
Purpose: Brain metastases can occur in up to 50% of patients with metastatic HER2-positive breast cancer. Because patients with active brain metastases were excluded from previous pivotal clinical trials, the central nervous system (CNS) activity of
Autor:
Donald P. McDonnell, John D. Norris, Ching-yi Chang, Suzanne E. Wardell, Sarah Sammons, Myles Brown, Rinath Jeselsohn, Steffi Oesterreich, Sandeep Artham, Rachid Safi, Sunghee Park, Jennifer G. Baker, Kaitlyn J. Andreano
The estrogen receptor (ER/ESR1) is expressed in a majority of breast cancers and drugs that inhibit ER signaling are the cornerstone of breast cancer pharmacotherapy. Currently, aromatase inhibitors are the frontline endocrine interventions of choice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06e02837e68b422e6bbee28a3fb031fa
https://doi.org/10.1158/1535-7163.c.6542740
https://doi.org/10.1158/1535-7163.c.6542740